Alexander B, Odake K, Lawlor D, Swanger M
Fed Proc. 1975 May;34(6):1429-40.
Despite more than 2 decades of research, the explanation of the long-known hemostatic failure consequent to the use of some natural and synthetic macromolecular agents as plasma substitutes remains obscure. Conventional clotting parameters are not significantly affected in vivo or in vitro. Dextran, hydroxyethyl starch, and many other colloid macromolecules precipitate Factors I and VIII, fibrin monomer, and perhaps v. W. (von Willebrand) factor(s) from plasma, rendering at least the first three insoluble, in relation to the molecule size and concentration of the colloid, and for dextran, its intrinsic viscosity. The precipitate, rich in Factors VIII and I, redissolves on warming, and reprecipitates on cooling, behaving as a cryo-Factor I. In composition it closely resembles the cryoprecipitate obtained by slow-thawing of plasma. Both clot faster with thrombin than the parent plasma. The amount precipitated from plasma by dextran or hydroxyethyl starch varies very widely from individual to individual. Cryo- of dextran-precipitable material can be obtained by interacting purified Factor I with a miniscule amount of thrombin. Dextran, hydroxyethyl starch, polyvinyl pyrrolidone, some forms of gelatin, and several polyamino acids accelerate thrombin clotting of normal plasma, several dysfibrinogenemic plasmas, or Factor I. Albumin, hemoglobin, some modified gelatins do not. Poor platelet thromboplastic function appears some hours after dextran infusion, associated with morphologic capillary abnormalities that strikingly resemble those in v. W. disease. We postulate that the hemostatic defect associated with the use of plasma substitutes is a form of induced v. W. disease or disseminated intravascular clotting, ensuing from precipitation and removal of v. W. factor(s), Factors VIII and I, microcirculatory abnormality, and platelet malfunction. The latter two supervene some time after administration of dextran. It reported antithrombotic activity is perhaps referable to the same action.
尽管经过了20多年的研究,但对于使用某些天然和合成高分子物质作为血浆代用品后长期存在的止血功能衰竭的解释仍不清楚。传统的凝血参数在体内或体外均未受到显著影响。右旋糖酐、羟乙基淀粉和许多其他胶体大分子会使血浆中的因子I、因子VIII、纤维蛋白单体以及可能的血管性血友病因子沉淀,相对于胶体的分子大小和浓度以及右旋糖酐的特性粘度而言,至少使前三者不溶。富含因子VIII和I的沉淀物在升温时重新溶解,冷却时再次沉淀,表现为冷沉淀因子I。其成分与通过血浆缓慢解冻获得的冷沉淀物非常相似。两者用凝血酶凝血的速度都比原血浆快。右旋糖酐或羟乙基淀粉从血浆中沉淀出的量在个体之间差异很大。通过将纯化的因子I与极少量的凝血酶相互作用,可以获得可被右旋糖酐沉淀物质的冷沉淀物。右旋糖酐、羟乙基淀粉、聚乙烯吡咯烷酮、某些形式的明胶以及几种多氨基酸可加速正常血浆、几种异常纤维蛋白原血症血浆或因子I的凝血酶凝血。白蛋白、血红蛋白、某些改性明胶则不能。输注右旋糖酐数小时后会出现血小板促凝功能不良,伴有形态学上的毛细血管异常,与血管性血友病极为相似。我们推测,与使用血浆代用品相关的止血缺陷是一种诱发的血管性血友病或弥散性血管内凝血形式,是由于血管性血友病因子、因子VIII和I的沉淀和清除、微循环异常以及血小板功能障碍所致。后两者在给予右旋糖酐一段时间后出现。其报道的抗血栓活性可能也归因于相同的作用。